Nebula Research & Development’s iTeos Therapeutics ITOS Stock Holding History

Nebula Research & Development’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-28,909	Closed	-$288K	–	437
2025 Q2	$288K	Buy	+28,909	New	+$233K	0.02%	801

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Nebula Research & Development's ITOS Position: Q3 2025 in Review

Nebula Research & Development sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 28,909 shares — an estimated $288K sold.

Nebula Research & Development first reported a position in ITOS in Q2 2025 and held it in 1 quarter. The position peaked at $288K in Q2 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

Nebula Research & Development reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
Nebula Research & Development sold 28,909 iTeos Therapeutics shares in Q3 2025, an estimated $288K.
Nebula Research & Development first reported a position in iTeos Therapeutics in Q2 2025 and held it in 1 quarter.
Nebula Research & Development's iTeos Therapeutics position peaked at $288K in Q2 2025.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.